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1. Introduction 
Radiation therapy is one of the most important treatment modalities for cancer therapy 
alongside surgery and chemotherapy. However, a major problem associated with radiation 
therapy in the clinical setting is that, in many cases, local control of the tumor cannot be 
achieved using this modality alone. This has driven researchers into radiosensitizers, i.e., 
compounds that enhance the intrinsic sensitivity of cancer cells to ionizing radiation (IR). 
Several compounds, including halogenated pyrimidines and nitroimidazole derivatives, 
show radiosensitizing effects in cancer cells [1]; however, clinical application of these 
compounds is limited because they are highly toxic to normal cell and tissues. Therefore, 
radiosensitizers with low toxicity to normal tissues are urgently needed. 
The principal target for IR-induced killing of cancer cells is DNA [2]. Of the different types of 
DNA damage generated by IR, DNA double-strand breaks (DSBs) are thought to be the most 
cytotoxic. DSBs induced by IR are preferentially repaired by non-homologous end joining 
(NHEJ) [3, 4], which joins the two broken DNA ends without the need for sequence homology. 
To enable NHEJ, the chromatin needs to be remodeled into an ‘open’ state so that the DNA 
repair proteins can access the DSB sites [5]. We previously reported that acetylation of histone 
proteins at DSB sites by the histone acetyltransferases (HATs), TIP60, CBP and p300, facilitates 
NHEJ through chromatin remodeling [6]. This suggests that the inhibition of HAT activity will 
radiosensitize cancer cells by suppressing NHEJ. In line with this, we and others demonstrated 
that several natural compounds with HAT-inhibitory activity are able to radiosensitize cancer 
cells [6-12]. Since some of these compounds are safe when administered to humans [13-15], 
they could potentially be used as radiosensitizers in a clinical setting. Here, we discuss the role 
of HATs in NHEJ, the radiosensitizing effects of compounds with HAT-inhibitory activity, and 
the prospects for the clinical application of these compounds. 
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2. Radiosensitization by HAT inhibition 
2.1. HATs are involved in chromatin remodeling required for DNA repair 
Chromosomal DNA and histones form a highly condensed structure known as chromatin. 
During the repair of DNA DSBs, the accessibility of DNA repair proteins to the DSB sites on 
chromosomal DNA is regulated by the relaxation of the chromosome structure via chromatin 
remodeling. Remodeling is mediated by both covalent (histone modifications, e.g., acetylation) 
and non-covalent (ATPase-dependent chromatin remodeling) interactions (Figure 1). Several 
studies show that the acetylation of histones located at the DSB sites is a critical step for DNA 
repair [16-18]; however, the HATs involved in NHEJ have not been fully identified. 
 
 
 
 
Figure 1. Chromatin remodeling is required for DSB repair. Both histone modifications and ATPase-
dependent chromatin remodeling are needed for efficient repair. 
2.2. Cell-based NHEJ activity assay 
We developed a new assay system for evaluating NHEJ repair of DSBs in the chromosomal 
DNA in living human cells [6, 18] because the existing NHEJ assays used only non-
chromosomal (i.e., plasmid) DNA. The assay design is outlined in Figure 2. The IRES-TK-
EGFP plasmid, which contains two recognition sites for I-SceI endonuclease [20] in the 
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reverse direction, was integrated into the chromosomal DNA of H1299 human lung cancer 
cells as a substrate for DSBs and subsequent NHEJ repair. Human genomic DNA does not 
contain I-SceI sites; therefore, the I-SceI protein transiently expressed after transfection of the 
I-SceI expression plasmid specifically cleaves the two I-SceI sites in the substrate DNA to 
yield DSBs with incompatible ends. This results in DSBs in the chromosomal DNA. NHEJ of 
the two broken DNA strands results in deletion of the herpes simplex virus-thymidine 
kinase (TK) open reading frame and leads to the production of a transcript that enables the 
translation of enhanced green fluorescent protein (EGFP) instead of the TK protein.  
 
 
 
Figure 2. Cell-based NHEJ activity assay [6]. Upper panel: Assay design. Two I-SceI sites (in the reverse 
direction) are indicated by the yellow arrow heads. The locations of the PCR primers used for 
quantitative PCR to monitor DSB introduction by I-SceI (uncut DNA) and subsequent joining (joined 
DNA) are indicated by the purple and red arrows, respectively. CMV, cytomegalovirus 
promoter/enhancer; IRES, internal ribosome entry site; pA, polyA signal. Lower panel: Factors essential 
for NHEJ of DSBs on chromosomal DNA.  
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Therefore, the efficiency of NHEJ can be assessed by monitoring EGFP production. In 
addition, the DSBs produced by I-SceI and the subsequent NHEJ of the two broken DNA 
strands can be monitored by quantitative PCR.  
Nucleotide sequencing of the joined DNA revealed that ligation required no (or very little) 
sequence homology between the DNA ends, indicating that the DNA ends were joined via 
NHEJ. In addition, the contribution of other factors essential for the NHEJ of incompatible 
DNA ends (whose involvement was indicated by in vitro and in vivo plasmid-based assays) 
was also confirmed in the present chromosome-based in vivo assay. These factors are KU80 
and DNA-PKcs (synapsis), Artemis and PALF (DNA end resection), POL and POL (gap 
filling), and LIG4 (ligation) [21, 22]. 
2.3. HATs involved in NHEJ 
To date, several distinct families of HAT proteins have been identified, including CBP, P300, 
PCAF, GCN5 and MYST (which includes TIP60) [23]. We investigated the effects of ablating 
CBP, P300, PCAF and TIP60 on NHEJ using the cell-based NHEJ activity assay. A decrease 
in the number of EGFP-positive cells was observed upon transfection with siRNA specific 
for CBP, P300 or TIP60, but not in cells transfected with siRNA specific for PCAF [6]. These 
results indicate that CBP, P300 and TIP60 are involved in NHEJ in human cells. 
2.4. Natural compounds with HAT activity suppress NHEJ activity 
Several compounds derived from natural ingredients show HAT-inhibitory activity (Table 
1). Curcumin, a major curcumanoid found in the spice turmeric, is a specific inhibitor of the 
homologous HATs, CBP and P300 [24]. Anacardic acid, derived from the shell of Anacardium 
occidentale (‘cashew nut’), inhibits P300, PCAF and TIP60 [7, 25, 26], and Garcinol, found in 
the rind of Garcinia indica (mangosteen), inhibits P300 and PCAF [27]. 
 
Compound MW1 Target 
HATs 
Other target proteins/pathways DER2 
Curcumin 368.38 CBP, P300 NF-B pathway, PI3K/mTOR/ETS2 
pathway, AP-1 STAT, LOX-1 
1.23 
Anacardic 
acid 
342.47 P300, PCAF, 
TIP60 
NF-B pathway, LOX-1, Xanthine oxidase,   1.51 
Garcinol 602.80 P300, PCAF NF-B pathway, Src, MAPK/ERK, PI3K/Akt 
pathways, topoisomerase I/II 
1.61 
1Molecular weight; 2Dose enhancement ratio (as assessed in cell viability assays [8]). 
Table 1. HAT inhibitors that suppress NHEJ in human cells. 
The cell-based NHEJ activity assay was used to investigate the effects of curcumin, 
anacardic acid, and garcinol on NHEJ; the results showed that treatment with each 
compound decreased the proportion of EGFP-positive cells (Figure 3) [6, 8]. This indicates 
that these HAT inhibitors suppress NHEJ activity in vivo.  
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Figure 3. Suppression of NHEJ by HAT inhibitors [6, 8]. H1299-dA3-1 #1 cells pretreated with curcumin 
(20 M), anacardic acid (50 M), or garcinol (12 M) were transfected with the I-SceI expression 
plasmid. (a) The proportion of EGFP-positive cells assessed by fluorescence-activated cell sorting 
analysis. (b,c) Proportion of joined (b) and uncut (c) DNA in cells assessed by quantitative PCR. The 
proportion of EGFP-positive cells and the proportion of joined DNA after garcinol treatment versus 
those in cells treated with DMSO (expressed as a ratio). The proportion of uncut DNA remaining after 
drug treatment expressed as a ratio of the amount of uncut DNA present after I-SceI transduction versus 
the amount present before transduction. Results 48 h after transfection of the I-SceI expression plasmid 
are shown. The results represent the mean ± s.d from three independent experiments. siCTR, non-
targeting siRNA. 
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2.5. HAT inhibitors radiosensitize cancer cells 
Because DNA DSBs induced by IR are preferentially repaired by NHEJ [3, 4], and HAT 
inhibitors suppress the activity of NHEJ, it is thought that HAT inhibitors may enhance the 
intrinsic sensitivity of cancer cells to IR. In line with this, the radiosensitizing effects of 
curcumin, anacardic acid and garcinol have been studied by ourselves and others both in 
vitro and in vivo (see Table 2); however, it is not certain that the observed radiosensitizing 
effects of these compounds is entirely due to their HAT-inhibitory activity, since they may 
also affect many other proteins or pathways considered to be important for the cancer cell 
survival (see Table 1). In our own study, garcinol showed the strongest radiosensitization 
effect of the compounds tested. A nontoxic concentration of garcinol (4 uM) inhibited NHEJ 
without significantly affecting the DNA damage checkpoint (Table 1) [8]. Further 
investigations into mechanisms underlying the radiosensitizing effects of HAT inhibitors are 
ongoing. 
 
 
Compound Cells/mice Cell lines Authors Year Journal 
Curcumin Cells & 
mice 
SCC1 Khafif A, et al.[9] 2009 The Laryngoscope 
 Cells HCT116 Sandur SK, et al.[10] 2009 Int J Radiat Oncol 
Biol Phys 
 Cells PC-3 Li M, et al.[11] 2007 Cancer Res 
 Cells PC-3 Chendil D, et al.[12] 2004 Oncogene 
Curcumin 
/anacardic acid 
Cells H1299 Ogiwara H, et al.[6] 2011 Oncogene 
Anacardic acid Cells SQ20B, 
SCC35, 
HeLa 
Sun Y, et al.[7] 2006 FEBS Lett 
Garcinol Cells A549, HeLa Oike, et al.[8] 2012 Int J Radiat Oncol 
Biol Phys 
 
Table 2. Radiosensitization by HAT inhibitors. 
2.6. Clinical studies using compounds with HAT-inhibitory activity 
There are several clinical studies reporting the administration of compounds with HAT-
inhibitory to humans (Table 3). Curcumin has been used, either alone or combined with 
radiation therapy and/or chemotherapeutic agents, to treat cancer patients, and garcinol has 
been used for weight-loss therapy. Although not all of the studies were designed to 
specifically evaluate the radiosensitizing effects of these compounds, the data will be of help 
to estimate their toxicity. The available data indicate that the side effects of these 
compounds are tolerable, at least when used alone. 
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Compound Disease Phase Modality Sponsor/Author 
Curcumin Rectal cancer II Curcumin, RT1, 
capecitabine vs. RT1, 
capecitabine 
M.D. Anderson 
Cancer Center 
Curcumin Pancreatic 
cancer 
II Curcumin, gemcitabine vs. 
gemcitabine 
Rambam 
Healthcare Campus 
Curcumin Pancreatic 
cancer 
II Curcumin alone M.D. Anderson 
Cancer Center 
Curcumin Colorectal cancer I Curcumin alone Sharma RA, et 
al.[13] 
Curcumin Healthy 
volunteer 
I Curcumin alone Lao CD, et al.[14] 
Garcinol Obesity II Garcinol, HCA2 acid vs. 
HCA2 
Sabinsa 
Corporation 
Garcinol Obesity II Garcinol, HCA2, forskolin, 
piperine 
Majeed M, et al.[15] 
 
Details on the clinical trials are available for inspection at:  
http://www.clinicaltrials.gov/ and http://www.garcitrin.com/clinical/.  
1Radiation therapy, 2Hydroxycitric acid. 
Table 3. Clinical studies using compounds with HAT-inhibitory activity. 
3. Conclusions/perspectives 
The growing incidence of cancer worldwide indicates that radiation therapy will become 
increasingly significant as a cancer treatment [28]. Enhancing the efficacy of IR against 
cancer cells is urgent needs local control of tumors. As discussed in this article, 
radiosensitization of cancer cells by compounds with HAT-inhibitory activity has been 
reported at the level of basic research. Clinical studies indicate that some of these 
compounds can be administered to human patients with low systemic toxicity. Taken 
together, the available data suggest that compounds with HAT-inhibitory activity are 
promising candidates for radiosensitizers that may be applicable in clinical settings. 
However, the detailed mechanisms by which these compounds radiosensitize cancer cells 
are still largely unknown. Moreover, it is unclear whether these compounds can achieve 
adequate levels of radiosensitization in humans at a dose that shows no (or at least low) 
toxicity. Further investigations will establish whether HAT inhibitors can be used clinically 
to radiosensitize cancer cells. 
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